You are here

Article Text

Article menu
Download PDFPDF
Correspondence
Concerns on glucocorticoid use for Japanese patients with established rheumatoid arthritis
  1. Hiroshi Oiwa
  1. Correspondence to Dr Hiroshi Oiwa, Department of Rheumatology, Hiroshima Shiritsu Hiroshima Shimin Byoin, Hiroshima 730-8518, Japan; hiroshioiwa{at}aol.com

https://doi.org/10.1136/annrheumdis-2017-212206

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    I read with great interest the recommendation for the management of rheumatoid arthritis (RA) by the European League Against Rheumatism (EULAR), especially the recommendation regarding glucocorticoid use: ‘Short-term glucocorticoids should be considered when initiating or changing conventional synthetic disease-modifying antirheumatic drugs (DMARDs), in different dose regimens and routes of administration, but should be tapered as rapidly as clinically feasible’.1 This recommendation was primarily supported by randomised controlled studies that suggested the efficacy and acceptable safety of glucocorticoids in early RA compared with placebo.1 2 However, I …

    View Full Text

    Footnotes

    • Competing interests HO reports personal fees from Astellas, Ayumi, Daiichi, Sankyo, Eisai, Dainippon Sumitomo, Chugai Pharmaceutical, outside the submitted work. HO has received lecture fees from Mitsubishi Tanabe, Takeda, AbbVie, Chugai, BMS, Astellas, Ayumi, Daiichi-Sankyo, Eisai, Asahi Kasei and Dainippon Sumitomo.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles